Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape

Login to access report north_east
Contact sales account_box

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 823 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.

Questions Answered in This Report:

  • How many biosimilar candidates are currently undergoing Phase I or III clinical development in a particular region?
  • Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
  • Which are the top 10 biosimilars developers by number of clinical stage candidates?
  • When is the expected launch date for late stage pipeline candidates in the seven major markets?
  • What is the level of competition expected for a brand, globally and by region/country?

Scope:

  • Markets covered: Global
  • Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.

Mentioned in This Report:

Key Companies Mentioned

  • Amgen
  • Allergan
  • Biocon
  • Celltrion
  • Dr. Reddy’s
  • Fresenius Kabi
  • Gedeon Richter
  • Intas
  • Merck & Co
  • Viatris
  • Pfizer
  • Samsung Bioepis
  • Sandoz
  • Shanghai Henlius Biotech

Key Drugs Mentioned

  • Aranesp
  • Avastin
  • Darzalex
  • Enbrel
  • Erbitux
  • Eylea
  • Forteo
  • Herceptin
  • Humira
  • Keytruda
  • Lantus
  • Lucentis
  • Neulasta
  • Neupogen
  • Opdivo
  • Prolia / Xgeva
  • Remicade
  • Rituxan / MabThera
  • Xolair

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Landscape & Forecast – Disease Landscape & Forecast (G7)
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate the itch…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east